Earnings Estimates Rising for Neurocrine (NBIX): Will It Gain?

Core Viewpoint - Investors are encouraged to consider Neurocrine Biosciences (NBIX) due to solid improvements in earnings estimates and positive short-term price momentum [1][9] Earnings Estimates - Analysts are increasingly optimistic about Neurocrine's earnings prospects, leading to higher estimates that are expected to positively impact the stock price [2] - The Zacks Rank system indicates a strong correlation between earnings estimate revisions and stock price movements, with Zacks 1 Ranked stocks historically generating an average annual return of +25% since 2008 [3] Current-Quarter Estimates - For the current quarter, Neurocrine is expected to earn $2.26 per share, reflecting a year-over-year increase of +126.0% [6] - Over the last 30 days, the Zacks Consensus Estimate for Neurocrine has risen by 9.08%, with six estimates moving higher and no negative revisions [6] Current-Year Estimates - The expected earnings for the full year are $6.55 per share, representing a +99.1% change from the previous year [7] - Similar to the current quarter, there has been a positive trend in estimate revisions for the current year, with six estimates moving up and no negative revisions [7] Zacks Rank - Neurocrine currently holds a Zacks Rank 1 (Strong Buy) due to favorable estimate revisions, which is a tool that helps investors leverage earnings estimate changes for investment decisions [8] - Research indicates that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [8] Stock Performance - Neurocrine's stock has gained 10.6% over the past four weeks, driven by solid estimate revisions and promising earnings growth prospects [9]